Hyphens Pharma net profit grows to $10.76m in 2024

Revenue also jumped 14.6% for the year.

Hyphens Pharma International Limited saw its total comprehensive income attributable rise to $10.76m in the full year ended 31 December 2024 up from $8.38m in the same period last year.

Revenue for the year reached a record of $195.4m up 14.6% from the previous year. The revenue jump was mostly attributed to to a 21.6% jump by the Specialty Pharma Principals business.

Meanwhile, the Proprietary Brands segment’s revenue grew by 7.4%, boosted by higher demand for Ceradan dermatological products, Ocean Health health supplement products, TDF dermocosmetic products and Novem nutraceutical products. Lastly, revenue from the Medical Hypermart and Digital segment also saw a modest increase of 2.1%.

Gross profit increased by 12.3% to S$69.5 million in FY2024, in tandem with increased sales. However, the gross profit margin decreased marginally from 36.3% in FY2023 to 35.6% in FY2024 due to an increase in the cost of sales from the principals and suppliers.

The group’s newly acquired Ardence Pharma Sdn Bhd contributed $7.2m in revenue.

Hyphens Pharma is proposing a final dividend of 1.50 Singapore cents per share for FY2024.

Follow the link for more news on

pharmaceuticals

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia